This will enable the firm to have a credible greenhouse gas (GHG) emissions calculation, and supply chain Environmental, Social, and Governance (ESG), which will helped achieve the EcoVadis Gold Medal.
Taisho Pharmaceuticals Philippines, a wholly owned subsidiary of Taisho Pharmaceutical, a leading health products manufacturer with subsidiaries and networks across America, Europe, and Asia, is joining the country’s move towards mandatory sustainability reporting.
While this takes effect only for listed companies for now, reporting requirements are increasingly cascading across value chains.
Hence, non-listed entities like Taisho Pharmaceuticals are experiencing trickle-down implications, with growing pressure from corporate customers, partners, and stakeholders to demonstrate credible sustainability performance.
With the pharmaceutical and healthcare industries contributing approximately 5% of global carbon emissions, the Philippines is uniquely positioned to shape sustainability practices across the sector.
Taisho Pharmaceuticals manufactures, imports, distributes, and manages pharmaceuticals and energy drinks, which leverages the country’s strategic position as one of Southeast Asia’s largest pharmaceutical markets—which generated nearly USD 2 billion in revenue in 2025 alone.
In this landscape, businesses are recognising sustainability as a strategic advantage, strengthening competitiveness, enhancing stakeholder trust, and positioning themselves ahead of increasing market and regulatory expectations.
Building on this momentum, Taisho Pharmaceuticals is actively driving ESG initiatives within its operations and supply chains and set a benchmark for the industry.
USING ESGPEDIA’S PLATFORM
To support these efforts, the company adopted ESGpedia’s ESG reporting platform, enabling enhanced sustainability reporting, robust carbon accounting, and streamlined supplier engagement.
Jennifer Ribultan, Taisho Philippines’ Internal Control Manager, Compliance Officer, Sustainability Lead, said: “ESGpedia is a scalable and efficient ESG reporting platform that has been instrumental in advancing our sustainability journey. It enhances our reporting capabilities, particularly in ESG report generation and emissions calculations, supporting us in optimising capital allocations while ensuring high-quality, automated reporting.”
With the goal of benchmarking its sustainability practices and performance against global standards, Taisho Pharmaceuticals pursued an EcoVadis assessment in 2022 to obtain an independent, third-party rating.
During the process, key hurdles were pointed out. Taisho, like many companies, faced limited in-house sustainability expertise to determine what metrics to track, as well as insufficient infrastructure to effectively manage and report ESG performance.
Engaging external consultants for guidance also posed budget constraints, making it difficult to develop a robust ESG report efficiently.
“We did not have in-house expertise to accurately measure key metrics such as carbon emissions or to determine the most appropriate standards aligned with our company size and sustainability maturity,” shared Ribultan.
Taisho Pharmaceuticals then decided to partner with ESGpedia, whom they connected with at an engagement organised by the Global Compact Network Philippines, to advance their sustainability reporting journey.
“The ESGpedia team provided a practical and scalable digital solution aligned with our needs and available resources. At that point, we recognised that ESGpedia was the right ESG solution partner to support our sustainability journey,” Taisho PH’s sustainability lead underscored.
TOOLS FOR TAISHO
With ESGpedia’s guidance and proactive advisory from experienced sustainability and data experts, Taisho Pharmaceuticals was able to identify the ESG topics most material and relevant to its business.
That provides it with a clear starting point to collect and track the essential ESG metrics and enabled the team to efficiently complete Global Reporting Initiative (GRI)-aligned questionnaires, which is then further simplified by built-in guidance notes on the platform.
“The platform has a structured approach with pre-aligned GRI questionnaires, providing clear guidance without requiring extensive in-house technical expertise,” shared Ribultan.
Leveraging ESGpedia’s ESG reporting platform, Taisho has effectively generated their audit-ready, GRI-aligned FY2023 and FY2024 Sustainability Reports.
That shifted their reliance away from manual processes and costly, lengthy consultancy services, while ensuring compliance, credibility, and accuracy.
Real-time dashboards and analytics also gave the company clear visibility into its ESG performance and progress against targets, delivering actionable ESG insights to strengthen decision-making.
In line with that, Taisho Pharmaceuticals Philippines also established a robust foundation in Scope 1 and 2 emissions reporting by making use of ESGpedia’s Carbon Calculator to systematically track and analyse the company’s carbon footprint and key emissions drivers.
To strengthen comprehensive sustainability disclosures and advance its supply chain decarbonisation strategy, Taisho Pharmaceuticals then utilized ESGpedia’s Supply Chain ESG module to implement a customised Supplier Engagement questionnaire—which actively engages its suppliers for enhanced visibility into value chain and Scope 3 emissions.
ECOVADIS ASSESSMENT, ACCELERATION OF TAISHO’S ESG PERFORMANCE
The ESGpedia team also guided Taisho Pharmaceuticals through its EcoVadis assessment, offering advisory and hands-on support throughout the process.
Furthermore, the implementation of ESGpedia’s platform for Sustainability Reporting, Carbon Accounting, and Supplier Engagement has significantly advanced Taisho Pharmaceuticals’ ESG progress and performance.
Key milestone achievements from the adoption of ESGpedia include enhanced sustainability and carbon disclosures; improved reputation and greater attractiveness to investors through the generation of GRI-aligned Sustainability Reports and the EcoVadis Gold Medal; enhanced supplier engagement and value chain sustainability; and heightened business competitiveness.
“While profitability remains a key priority, Taisho Pharmaceutical’s impact on the environment and society is increasingly recognised as a critical driver of long-term, sustainable value creation,” Ribultan explained.
She continued, “ESGpedia has proven to be a valuable partner, helping us track and showcase our sustainability progress while providing real-time insights that allow us to adjust targets and align strategies effectively.”
ESGpedia is Asia’s leading ESG data and technology company, headquartered in Singapore and has presence in over 10 Asia-Pacific countries.
The platform serves as a one-stop digital platform for sustainability, empowering more than 1,000 corporations, SMEs, and financial institutions in achieving ESG excellence and various sustainability outcomes.
It provides end-to-end ESG solutions, covering digital data management, carbon calculation, ESG reporting, supply chain ESG, and sustainable finance.